Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers

Journal of Hepatology

Volumn 44, Issue 5, 2006, Pages 886-893

  Loureiro Silva, Mauricio R ^a,b   Iwakiri, Yasuko ^a,b   Abraldes, Juan G ^a,b   Haq, Omar ^a,b   Groszmann, Roberto J ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Liver perfusion; Microcirculation; S nitroso N acetylpenicillamine; Soluble guanylyl cyclase

Indexed keywords

METHOXAMINE; N ACETYL S NITROSOPENICILLAMINE; N(G) METHYLARGININE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; DRUG EFFECT; INCUBATION TIME; LIVER CIRRHOSIS; LIVER PERFUSION; LIVER SINUSOID; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE PRESSURE; VASODILATATION; WESTERN BLOTTING;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; ENZYME INHIBITORS; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 33645757093     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.01.032     Document Type: Article

References (53)

1. Groszmann R.J., Kravetz D., Bosch J., Glickman M., Bruix J., Bredfeldt J., et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology 2 (1982) 757-762
2. Navasa M., Chesta J., Bosch J., and Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 96 (1989) 1110-1118
3. Albillos A., Llebo J.L., Banares R., Rossi I., Iborra J., Calleja J.l., et al. Hemodynamic effects of α-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 20 (1994) 611-617
4. Bhathal P.S., and Grossman H.J. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1 (1985) 325-337
5. Pinzani M., Milani S., De Franco R., Grappone C., Caligiuri A., Gentillini A., et al. Endothelin 1 is overexpressed in human cirrhotic liver and exert multiple effect on activated hepatic stellate cells. Gastroenterology 110 (1996) 534-548
6. Graupera M., Garcia-Pagan J.C., Abraldes J.G., Peralta C., Bragulat M., Corominola H., et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 37 (2003) 172-181
7. Gupta T.K., Toruner M., Chung M.K., and Groszmann R.J. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28 (1998) 926-931
8. Rockey D.C., and Chung J.J. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114 (1998) 344-351
9. Wiest R., and Groszmann R.J. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35 (2002) 478-491
10. Dudenhoefer A.A., Loureiro-Silva M.R., Cadelina G.W., Gupta T., and Groszmann R.J. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology 36 (2002) 381-385
11. Carvajal J.A., Germain A.M., Huidobro-Toro J.P., and Weiner C.P. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 184 (2000) 409-420
12. Waldman S.A., and Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 39 (1987) 163-169
13. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 84 (1987) 9265-9269
14. Moncada S., Palmer R.M.J., and Higgs E.A. Nitric oxide pathway: physiology, pathophysiology and pharmacology. Pharmacol Rev 43 (1991) 109-142
15. Moncada S., and Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329 (1993) 2002-2012
16. Mullershausen F., Russwurm M., Thompson W.J., Liu L., Koesling D., and Friebe A. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155 (2001) 271-278
17. Nagaoka T., Shirakawa T., Balon T.W., Russell J.C., and Fujita-Yamaguchi Y. Cyclic nucleotide phosphodiesterase 3 expression in vivo. Diabetes 47 (1998) 1135-1144
18. Netherton S.J., Jimmo S.L., Palmer D., Tilley D.G., Dunkerley H.A., Raymond D.R., et al. Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells. Diabetes 51 (2002) 1194-1200
19. Matsumoto T., Kobayashi T., and Kamata K. Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol 285 (2003) H283-H291
20. Yamamoto S., Nishizawa S., Yokoyama T., Ryu H., and Uemura K. Subarachnoid hemorrhage impairs cerebral blood flow response to nitric oxide but not to cyclic GMP in large cerebral arteries. Brain Res 757 (1997) 1-9
21. Sobey C.G., and Quan L. Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage. Am J Physiol Heart Circ Physiol 277 (1999) H1718-H1724
22. MacLean M.R., Johnston E.D., McCulloch K.M., Pooley L., Houslay M.D., and Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 283 (1997) 619-624
23. Murray F., MacLean M.R., and Pyne N.J. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137 (2002) 1187-1194
24. Eardley I., Ellis P., Boolell M., and Wulff M. Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction. J Clin Pharmacol 53 (2002) 61S-65S
25. Desouza C., Parulkar A., Lumpkin D., Akers D., and Fonseca V.A. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25 (2002) 1336-1339
26. Michelakis E.D., Tymchak W., Noga M., Webster L., Wu X.C., Lien D., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108 (2003) 2066-2069
27. Mikhail G., Prasad S.K., Li W., Rogers P., Chester A.H., Bayne S., et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 25 (2004) 431-436
28. Lopez-Novoa J.M. Pathophysiological features of carbon tetrachloride/phenobarbital model of experimental liver cirrhosis in rats. In: Epstein M. (Ed). The kidney in liver disease. 3rd ed (1988), Elsevier, New York 309-327
29. Loureiro-Silva M.R., Cadelina G.W., and Groszmann R.J. Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and post-sinusoidal areas. Am J Physiol Gastrointest Liver Physiol 284 (2003) G567-G574
30. Hamilton R.L., Berry M.N., Williams M.C., and Severinghaus E.M. A simple and inexpensive membrane lung for small organ perfusions. J Lipid Res 15 (1974) 182-186
31. Grossman H.J., and Bhathal P.S. Application of isolated perfused rat liver preparation to pharmacological studies of the intrahepatic vascular bed. Methods Find Exp Clin Pharmacol 6 (1984) 33-40
32. Gores G.J., Kost L.J., and LaRusso N.F. The isolated perfused rat liver: conceptual and practical considerations. Hepatol Baltimore 6 (1986) 511-517
33. Moncada S., Rees D.D., Schulz R., and Palmer R.M.J. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 88 (1991) 2166-2170
34. Balard S.A., Gingeli C.J., Tang K., Turner L.A., Price M.E., and Naylor A.M. Affect of sildenafil on the relaxation of the human corpus cavernosum tissu in vitro and on the activities of cyclic nucleotide phosphodiesterase isoenzymes. J Urol 159 (1998) 2164-2171
35. Villeneuve J.-P., Dagenais M., Huet P.-M., Roy A., Lapoint R., and Marleua D. The hepatic microcirculation in the isolated perfused human liver. Hepatology 23 (1996) 24-31
36. Hung D.Y., Chang P., Cheung K., Winterford C., and Roberts M.S. Quantitative evaluation of altered hepatic spaces and membrane transport in fibrotic rat liver. Hepatology 36 (2002) 1180-1189
37. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 271 (1996) C1424-C1437
38. 4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive models with healthy controls. Comp Hepatol 2 (2003) 2
39. Frei B., England L., and Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 86 (1989) 6377-6381
40. Bellamy T.C., Wood J., and Garthwaite J. On the activation of soluble guanylyl cyclase by nitric oxide. Proc Natl Acad Sci USA 99 (2002) 507-510
41. Andreopoulos S., and Papapetropoulos A. Molecular aspects of soluble guanylyl cyclase regulation. Gen Pharmacol 34 (2000) 147-157
42. Ujiie K., Hogarth L., Danziger R., Drewett J.G., Yuen P., Pang I.H., et al. Homologous and heterologous desensitization of a guanylyl cyclase-linked nitric oxide receptor in cultured rat medullary intersticial cells. J Pharmacol Exp Ther 270 (1994) 761-767
43. Filippov G., Bloch D., and Bloch K. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 100 (1997) 942-948
44. Ortiz M.C., Fortepiani L.A., Martinez C., Atucha N.M., and Garcia-Estan J. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: role of nitric oxide and endothelium. Clin Sci 91 (1996) 733-738
45. Lin C.S., Chow S., Lau A., Tu R., and Lue T.F. Human PDE5 gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 14 (2002) 15-24
46. Muriel P., and Mourelle M. Characterization of membrane fraction lipid composition and function of cirrhotic rat liver. Role of S-adenosyl-l-methionine. J Hepatol 14 (1992) 16-21
47. Morales-Ruiz M., Cejudo-Martin P., Fernandez-Varo G., Tugues S., Ros J., Angeli P., et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 125 (2003) 522-531
48. Wilkens H., Guth A., König J., Forestier N., Cremers B., Hennen B., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
49. Ghofrani H.A., Wiedermann R., Rose F., Olschewski H., Schermuly R.T., Weissmann N., et al. Combination therapy with sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
50. Michelakis E.D., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary hypertension. Circulation 105 (2002) 2398-2403
51. Ghofrani H.A., Schrmuly R.T., Rose F., Wiedemann R., Kohstall M.G., Kreckel A., et al. Sildenafil for long-term treatment of non-operable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167 (2003) 1139-1141
52. Stiebellehner L., Petkov V., Vonbank K., Funk G., Schenk P., Ziesche R., et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary hypertension. Chest 123 (2003) 1293-1295
53. Colle I., De Vries A.S., Van Vlierberghe H., Lameire N.H., and DeVos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int 24 (2004) 63-68